The biotech industry is at the threshold of a radically different paradigm for drug discovery, enabled by high throughput in vivo screening technology. Read more about the importance and impact of this methodology:
Shouldn’t aging be part of drug discovery for diseases of aging?
Gordian exists to move therapeutic testing from plastic wells and young mice into a living environment with all the complexity present in patients with age-related disease.
We’re now
To cure age-related diseases, shouldn’t we study aged animals? 🐴🐒
The answer is yes, and Gordian makes this possible with our singular in vivo gene therapy screening platform.
@TheAlexKnapp
explains how this could change industry standards in
@Forbes
:
We’re grateful to our longtime friend and lead investor
@LauraDeming
for her insights, inspiration, and support. We’re excited to change what it means to “grow old together” with you, and to have all the time in the world ⏳
We have a big presence at the
@americanaging
's annual meeting next week in Madison, WI. The theme is Integrative Approaches to Geroscience.
@MartinBJensen
will do a roundtable on Sunday and a panel presentation on Tuesday. Preclinical development scientist Gavin Pharaoh has the
The whole Gordian office was psyched to welcome biotech celebrity
@bradloncar
from
@BiotechTVHQ
at New Pella (aka Gordian HQ) to talk about early results from our platform. Tune in here:
We're grateful for investors who trust our vision of how drug discovery could work so much better, and march alongside us in this journey, including The Longevity Fund, Arctica Ventures, Athos Service GmbH,
@gigafund
,
@foundersfund
,
@fiftyyears
, former
@Novartis
CEO Thomas
Most of us imagine our golden years as vibrant, independent, and activity-filled, enjoying leisure time with family and friends. The reality is often very different, with chronic illness, pain, dependence on caregivers, and hospital time. 2/15
Scientific breakthroughs don’t come from one “aha” moment or a single silver-bullet solution.
The Gordian platform is no different. The results unveiled today have been 5+ years in the making, and it’s just the beginning.
Watch our animated explainer here:
Please share:
@GordianBio
seeks a leader of teams spanning molecules and sequencing data, to take over the application and development of our core Mosaic Screening technology!
Read more below or in listing:
The May editorial in
@NatureBiotech
highlights the need for better model systems and large-scale data in understanding complex diseases, specifically MASH.
The piece spotlights
@GordianBio
's Mosaic Screening technology as a way to test many therapies simultaneously inside a
We have developed the world's first in vivo asset discovery factory, finding both novel targets and ways to target them in one screen, accelerating the path for our programs to reach the clinic In this way, we achieve our mission: curing age-related disease. 14/15
Who says money can’t buy time?: We are currently looking for several new members, mission-aligned investors, and expert advisors on biology and drug development to join us in our journey. Please reach out to us. 15/15
Next, we extract and sequence single cells from the treated tissue and use the intervention’s unique barcodes to identify the specific treatment present in each cell. The single-cell transcriptome allows us to explore various aspects of disease biology simultaneously in an
To achieve this, we have to start testing therapies in the context of what drives these illnesses: aging. We must unclog the bottleneck of animal testing, especially for complex age-related diseases, and turn the tide of repeated failed clinical trials. Sounds great, but how?
The real test of a screening platform is its ability to predict clinically relevant outcomes, and in this experiment, the fraction of Pythia predictions matching validation results was a remarkable 80%. 11/15
Mosaic Screening: rather than picking a single target from literature or doing big screens in plastic wells to move the best guesses into animals one at a time, Gordian tests hundreds of therapies simultaneously in one sick animal. 6/15
We introduce a pooled library of gene therapies into the target tissue, turning it into a “mosaic.” Various cells scattered throughout the tissue receive different individual therapies, each with a unique barcode, separated not by wells of plastic but by unperturbed diseased
Who doesn’t love a good origin story?
Delve into the trials and triumphs of
@MartinBJensen
and
@leportfr
, from their respective childhoods on different continents to their first meeting at a San Francisco bakery, arguing about fruit flies, building an Art Car at Burning Man, and
For example, Gordian’s osteoarthritis (OA) screens are done in horses that acquired the disease naturally. Using our AI-powered analysis, Pythia, we’ve validated screen predictions by measuring cartilage regeneration capacity in patient-derived human cells to discover three novel
Today, Gordian is focused on four target indications: osteoarthritis (OA), metabolic dysfunction-associated steatohepatitis (MASH), heart failure with preserved ejection fraction (HFpEF), and pulmonary fibrosis. However, the platform can be applied to neurodegenerative,
Co-founder and CSO
@MartinBJensen
will speak this Saturday at Edge Esmeralda, a "popup village" for people who are working to make the world a better place. The event has five themes:
1. Health, longevity, & bio (Martin’s area)
2. Artificial intelligence
3. Hard tech
4. Human
When most drugs fail in clinical trials, improving predictive validity is how we can best help patients and why we built our technology to run the most patient-predictive in vivo experiments at a scale previously thought impossible. 12/15
We’re back from last week’s 24th American Society for Cell and Gene Therapy Annual Meeting (
#ASGCT24
), and as usual had an incredible time.
Our big takeaway is that advances in manufacturing, improvements in targeting, and reductions in toxicity are accelerating the push toward
Gors in the Wild:
@MartinBJensen
just wrapped his talk on the main stage at
#synbiobeta2024
where he enlightened like minds on how the Gordian platform tests hundreds of gene therapies simultaneously in a single animal. Also, we like that his outfit matches the decor!
Patient Avatars are advanced animal models of species and etiology representative of human patients. Imagine the predictive benefits of testing in an environment with an immune system, blood, hormones, and the full suite of cells in the 3D structure of living tissue, and add
Congratulations to
@bradloncar
and his team at
@BiotechTVHQ
for being named Media Commentator of the Year at the European Mediscience Awards 2024. We’re longtime fans of the show and were honored to meet Brad in person when he visited New Pella (Gordian HQ) in April.
Thanks to everyone who watches and enjoys BiotechTV. Sharing this award with
@AliGormanTV
,
@BrianOrelli
and our growing team. BiotechTV is just getting started.
Here’s a peek at our latest Happy Hour with Character Bio and
@DeepOriginBio
! A big thanks to our fascinating speaker, Stanford PhD student
@exnx
. Eric gave us the fine points of his genomic foundation model, Evo, and even got some insightful feedback from the audience.
See Gordian co-founder and CSO
@MartinBJensen
’s post about a big study from the LITMUS consortium examining the best dietary models of
#MASH
in mice based on their proximity to human patients. This thinking is very aligned with our Patient Avatars concept, focusing on models that
Great work - public resources qualifying and benchmarking disease models will help researchers who aren't exposed to patients or drug discovery avoid work that's "translational in name only". And this study is comprehensive and nuanced in assessing relevance to patients.
Fate, destiny, kismet… Nah! We’re scientists!
Even so, how the circuitous paths of co-founders
@leportfr
and
@MartinBJensen
intersected from across the globe makes us wonder.
ICYMI, find out how it all went down in “Fruit Flies, Burning Man, and Raging Against Aging: The
Take a Deep Breath! The Gordian Lung Crew just posted its take on the 120th American Thoracic Society conference. This year’s ATS meeting was inspiring in terms of progress in research and treatment, and also in how much more is needed. Learn more here:
Shouldn’t aging be part of drug discovery for diseases of aging?
Gordian exists to move therapeutic testing from plastic wells and young mice into a living environment with all the complexity present in patients with age-related disease.
We’re now
We are hiring! Come use pooled in vivo therapeutic screening to cure complex diseases of aging.
We currently have roles for:
🧬 Molecular biologist
🧪 Research Associates (MolBio, histology, animals)
🥼 Single cell experimentalist
Read & apply:
Taking this from invention to impact calls for a biotechnologist obsessed with operational excellence and with the strategic savvy to apply our platform in new ways that further improve predictive validity for clinical outcomes.
We congratulate Kitov Pharmaceuticals on its recent success in a late-stage study of its lead drug, which reduces pain caused by osteoarthritis (OA) without increasing the risk of heart disease, covered by
@Reuters
journalist
@RosmiShaji
here:
Indeed,
We wish BiotechTV all the best and look forward to more insightful biotech content. Meanwhile, if you missed our interview, check it out here:
#CreatingTime
#BioTech
#Entrepreneurship
Our biggest takeaway is that idiopathic pulmonary fibrosis (IPF) is a tough nut to crack, and patients need better treatment options. We learned a lot about how, like Gordian, many are working hard to develop better models to improve the translation of preclinical results into
Our innovators have made it possible to test hundreds of candidate therapies for efficacy simultaneously in small or large animal models most resembling patients with complex diseases, and we're already discovering novel hits.
For example, Gordian’s osteoarthritis (OA) screens are done in horses that acquired the disease naturally. Using our AI-powered analysis, Pythia, we’ve validated screen predictions by measuring cartilage regeneration capacity in patient-derived human cells to discover three novel
The real test of a screening platform is its ability to predict clinically relevant outcomes, and in this experiment, the fraction of Pythia predictions matching validation results was a remarkable 80%. 11/15
We wish BiotechTV all the best and look forward to more insightful biotech content. Meanwhile, if you missed our interview, check it out here.:
#CreatingTime
#BioTech
#Entrepreneurship